LABFF (Laboratorios Farmaceuticos Rovi) Cyclically Adjusted Book per Share: $13.83 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LABFF Laboratorios Farmaceuticos Rovi SA LABFF
99 GF Score
Price $67.17
GF Value $85.89
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Laboratorios Farmaceuticos Rovi Cyclically Adjusted Book per Share?

Laboratorios Farmaceuticos Rovi LABFF 99 Cyclically Adjusted Book per Share is $13.83 as of Jun. 2026. GuruFocus rates LABFF with a GF Score™ of 99/100 and a GF Value™ of $85.89 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Laboratorios Farmaceuticos Rovi's adjusted book value per share for the three months ended in Jun. 2026 was $15.783. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $13.83 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Laboratorios Farmaceuticos Rovi's average Cyclically Adjusted Book Growth Rate was 14.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 14.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 16.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Laboratorios Farmaceuticos Rovi was 18.20% per year. The lowest was 14.40% per year. And the median was 15.60% per year.

As of today (2026-08-25), Laboratorios Farmaceuticos Rovi's current stock price is $67.17. Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $13.83. Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PB Ratio of today is 4.86.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Laboratorios Farmaceuticos Rovi was 16.48. The lowest was 5.54. And the median was 8.23.


Laboratorios Farmaceuticos Rovi  (OTCPK:LABFF) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=67.17/13.83
=4.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Laboratorios Farmaceuticos Rovi was 16.48. The lowest was 5.54. And the median was 8.23.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Laboratorios Farmaceuticos Rovi Cyclically Adjusted Book per Share Related Terms


Laboratorios Farmaceuticos Rovi Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorios Farmaceuticos Rovi Cyclically Adjusted Book per Share Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.35 7.78 5.50 10.38 11.72

Laboratorios Farmaceuticos Rovi Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.78 12.29 11.72 9.55 13.83

LABFF vs ZTS, UTHR, VTRS: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PB Ratio falls into.


LABFF
99GF Score
Laboratorios Farmaceuticos Rovi SA LABFF
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laboratorios Farmaceuticos Rovi Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Laboratorios Farmaceuticos Rovi's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=15.783/131.3300*131.3300
=15.783

Current CPI (Jun. 2026) = 131.3300.

Laboratorios Farmaceuticos Rovi Quarterly Data

Book Value per Share CPI Adj_Book
201609 4.077 99.737 5.368
201612 3.926 101.842 5.063
201703 4.124 100.896 5.368
201706 4.332 101.848 5.586
201709 4.627 101.524 5.985
201712 4.600 102.975 5.867
201803 4.966 102.122 6.386
201806 4.575 104.165 5.768
201809 4.759 103.818 6.020
201812 5.906 104.193 7.444
201903 6.008 103.488 7.624
201906 6.107 104.612 7.667
201909 6.241 103.905 7.888
201912 6.468 105.015 8.089
202003 6.709 103.469 8.516
202006 7.161 104.254 9.021
202009 7.856 103.521 9.966
202012 8.207 104.456 10.318
202103 8.540 104.857 10.696
202106 8.783 107.102 10.770
202109 9.625 107.669 11.740
202112 9.708 111.298 11.455
202203 8.694 115.153 9.915
202206 7.903 118.044 8.792
202209 8.526 117.221 9.552
202212 10.518 117.650 11.741
202303 11.598 118.948 12.805
202306 10.488 120.278 11.452
202309 11.104 121.343 12.018
202312 11.351 121.300 12.290
202403 11.012 122.762 11.781
202406 10.019 124.409 10.576
202409 11.905 123.121 12.699
202412 11.711 124.753 12.328
202503 12.468 125.531 13.044
202506 12.710 127.251 13.117
202509 14.267 126.840 14.772
202512 15.211 128.400 15.558
202603 15.232 129.860 15.404
202606 15.783 131.330 15.783

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $13.83 mean?
Laboratorios Farmaceuticos Rovi (LABFF) has a Cyclically Adjusted Book per Share of $13.83 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Laboratorios Farmaceuticos Rovi and its competitors.
Is Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Book per Share too high?
Laboratorios Farmaceuticos Rovi's current Cyclically Adjusted Book per Share is $13.83. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Book per Share compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Book per Share of $13.83 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current Cyclically Adjusted Book per Share is $13.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (LABFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $85.89, compared to a current price of $67.17 — trading 21.8% below its estimated fair value. The current Cyclically Adjusted Book per Share is $13.83. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Cyclically Adjusted Book per Share is $13.83 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be undervalued. The current stock price of $67.17 is trading 21.8% below its estimated GF Value™ of $85.89. GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Undervalued.

Key valuation signals for LABFF:

  • Cyclically Adjusted Book per Share: $13.83
  • GF Value™: $85.89 vs. price of $67.17 (21.8% below fair value)
  • GF Score™: 99/100 with 2 warning signs

No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
99GF Score

Get the complete analysis for LABFF

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$67.17
Price
$85.89
GF Value